Form 4: ALX Oncology Executive Jaume Pons Reports Stock Option Grant

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., was granted 50,000 employee stock options.

Summary

• Jaume Pons, the President and Chief Scientific Officer of ALX Oncology Holdings Inc., has reported a transaction involving the acquisition of 50,000 employee stock options.
• These options were granted on January 21, 2025, at an exercise price of $1.65 per share.
• The options vest in 48 equal monthly installments starting on February 21, 2025, and expire on January 20, 2035.
• The reporting was made via a Form 4 filing with the SEC, which also included a power of attorney document.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for incentivizing executives in the biotech industry.
• The vesting schedule of 48 months is typical for such grants, encouraging long-term commitment.
• The exercise price is set at a specific value, which is common practice.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it incentivizes the executive to increase the company's value.
• The grant has no immediate impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, insider trading, executive compensation, Form 4, ALX Oncology, ALXO, Jaume Pons